A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

June 6, 2014

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Epilepsy
Interventions
DRUG

Perampanel

Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment

Trial Locations (42)

1070

Hôpital Erasme, Brussels

1130

Krankenhaus Wien-Hietzing, Vienna

3000

Uz Leuven, Leuven

4020

Kepler Universitätsklinikum, Linz

6020

Universitatsklinikum Innsbruck, Innsbruck

22100

Western Galilee Hospital, Nahariya

31096

Rambam Medical Center, Haifa

49202

Schneider Children's Medical Center Of Israel, Petah Tikva

58100

Edith Wolfson Medical Center, Holon

58185

Universitetssjukhuset I Linköping, Linköping

64239

Tel-Aviv Sourasky Medical Center, Tel Aviv

72200

Cerebrovaskularni Poradna S.R.O., Ostrava

4428164

Meir Medical Center, Kfar Saba

Unknown

Eisai Site# 2405, Battice

Eisai Site# 2404, Brussels

Eisai Site# 2406, Duffel

Eisai Site# 2409, Liège

Eisai Site# 2403, Ottignies

Eisai Site# 2408, Ruddershove

Eisai Site# 2407, Woluwe-Saint-Lambert

Eisai Site# 2402, Yvoir

Eisai Site# 2601, Beroun

Eisai Site# 2600, Brno

Eisai Site# 2606, Hradec Králové

Eisai Site# 2602, Náchod

Eisai Site# 2603, Prague

Eisai Site# 2013, Beersheba

Kiryat Hadassah, Jerusalem

The Chaim Sheba Medical Center, Ramat Gan

Eisai Site# 2003, Tel Aviv

Eisai Site# 2012, Tel Aviv

Eisai Site# 2008, Tel Litwinsky

Eisai Site# 1607, Bristol

Eisai Site# 1611, Lincoln

Eisai Site# 1604, London

Eisai Site# 1608, London

Eisai Site# 1609, London

Great Ormond Street hospital, London

Eisai Site# 1612, Newcastle

Eisai Site# 1606, Truro

SE-41345

Sahlgrenska Universitetssjukhuset, Gothenburg

Dd1 9Sy

Ninewells Hospital, Dundee

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT02033902 - A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years | Biotech Hunter | Biotech Hunter